In the last quarter, BioNTech posted a stark revenue decline of 43% year-over-year. Indeed, vaccine demand is lower compared to last year. Still, the company established flexible contracts for 2023. It will continue to fulfill those contracts in 2023 and beyond. Thus as the vibrant constantly evolves, BioNTech will continue to provide updates about the vaccine's efficacy.